168 related articles for article (PubMed ID: 37932205)
21. Real world data on IO-based therapy for metastatic renal cell carcinoma.
Stühler V; Herrmann L; Rausch S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3249-3258. PubMed ID: 35907009
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
[TBL] [Abstract][Full Text] [Related]
24. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
Navani V; Ernst M; Wells JC; Yuasa T; Takemura K; Donskov F; Basappa NS; Schmidt A; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; Powles T; McKay RR; Weickhardt A; Suarez C; Kapoor A; Lee JL; Choueiri TK; Heng DYC
JAMA Netw Open; 2022 Jun; 5(6):e2216379. PubMed ID: 35687336
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
26. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
27. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH
Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
29. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract][Full Text] [Related]
30. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
[TBL] [Abstract][Full Text] [Related]
31. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Fiala O; Buti S; Bamias A; Massari F; Pichler R; Maruzzo M; Grande E; De Giorgi U; Molina-Cerrillo J; Seront E; Calabrò F; Myint ZW; Facchini G; Kopp RM; Berardi R; Kucharz J; Vitale MG; Pinto A; Formisano L; Büttner T; Messina C; Monteiro FSM; Battelli N; Kanesvaran R; Büchler T; Kopecký J; Santini D; Giudice GC; Porta C; Santoni M
Target Oncol; 2024 May; ():. PubMed ID: 38704759
[TBL] [Abstract][Full Text] [Related]
32. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
[TBL] [Abstract][Full Text] [Related]
33. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
34. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinoma.
Xie R; Shang B; Shi H; Bi X; Song Y; Qu W; Bai H; Hu L; Wu J; Cui H; Du G; Guo L; Zheng S; Ying J; Li C; Ma J; Zhou A; Shou J
Cancer Med; 2023 Dec; 12(24):21807-21819. PubMed ID: 38018346
[TBL] [Abstract][Full Text] [Related]
36. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
Chablani PV; Karrison T; Stadler WM
Clin Genitourin Cancer; 2022 Dec; 20(6):510-514. PubMed ID: 35869002
[TBL] [Abstract][Full Text] [Related]
38. Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.
Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Massari F
Future Oncol; 2022 Feb; 18(5):625-634. PubMed ID: 34927453
[No Abstract] [Full Text] [Related]
39. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Chen YW; Rini BI
Curr Oncol Rep; 2022 Jun; 24(6):695-702. PubMed ID: 35247142
[TBL] [Abstract][Full Text] [Related]
40. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]